M J Edelman

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. doi Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status
    Martin J Edelman
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD21201 1595, USA
    J Clin Oncol 31:1990-6. 2013
  2. ncbi Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
    J Thorac Oncol 7:1618-21. 2012
  3. doi Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view
    Martin J Edelman
    Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Thorac Oncol 7:1331-6. 2012
  4. doi Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Clin Lung Cancer 13:171-80. 2012
  5. doi CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Thorac Oncol 7:649-54. 2012
  6. ncbi An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Martin J Edelman
    Department of Medical Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Semin Oncol 32:S3-8. 2005
  7. ncbi The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, 21201, USA
    Clin Lung Cancer 7:S64-6. 2005
  8. ncbi Second-line chemotherapy and beyond for non-small-cell lung cancer
    Martin J Edelman
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21126, USA
    Clin Adv Hematol Oncol 2:373-8. 2004
  9. ncbi Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    Martin J Edelman
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, 22 S Greene St, Baltimore, MD 21201 1595, USA
    J Clin Oncol 23:5774-8. 2005
  10. ncbi Lung cancer - Second Annual Winter Conference
    Martin J Edelman
    University of Maryland, Division of Hematology Oncology, Greenebaum Cancer Center, Baltimore, 21201, USA
    IDrugs 8:366-9. 2005

Research Grants

  1. CANCER AND LEUKEMIA GROUP B
    Martin Edelman; Fiscal Year: 2002
  2. PHASE I TRIALS OF ANTICANCER AGENTS
    Martin Edelman; Fiscal Year: 2002

Detail Information

Publications81

  1. doi Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status
    Martin J Edelman
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD21201 1595, USA
    J Clin Oncol 31:1990-6. 2013
    ..This randomized phase II study evaluated ixabepilone-based chemotherapy in stage IIIb/IV NSCLC, compared with paclitaxel-based chemotherapy. Tumor specimens were prospectively evaluated for β3T expression...
  2. ncbi Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
    J Thorac Oncol 7:1618-21. 2012
    ..The objective of this study was to determine the activity of EC145 in patients with chemotherapy refractory lung adenocarcinoma, whose tumors expressed the FR as determined by EC20 imaging...
  3. doi Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view
    Martin J Edelman
    Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Thorac Oncol 7:1331-6. 2012
    ..We raise several issues regarding the design and execution of these studies, which question the validity of these conclusions, and explore aspects of the trial results concerning the optimal use of this approach, if it is to be accepted...
  4. doi Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Clin Lung Cancer 13:171-80. 2012
    ..Although a phase II study failed to show superior outcome in patients with β III tubulin overexpression, other aspects of the epothilones argue for their continued development...
  5. doi CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Thorac Oncol 7:649-54. 2012
    ....
  6. ncbi An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Martin J Edelman
    Department of Medical Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Semin Oncol 32:S3-8. 2005
    ..Numerous questions have arisen regarding how to best incorporate EGFR-targeted agents into patient management, as well as the role of the clinical laboratory in these decisions and the design of future trials...
  7. ncbi The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, 21201, USA
    Clin Lung Cancer 7:S64-6. 2005
    ..This article will review the rationale for the use of bortezomib as part of the chemotherapy/RT strategy for the treatment of NSCLC...
  8. ncbi Second-line chemotherapy and beyond for non-small-cell lung cancer
    Martin J Edelman
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21126, USA
    Clin Adv Hematol Oncol 2:373-8. 2004
    ..Numerous other agents with diverse mechanisms are currently undergoing evaluation in this setting. This review evaluates the population eligible for such treatments and discusses recent trials in second and subsequent lines of therapy...
  9. ncbi Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    Martin J Edelman
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, 22 S Greene St, Baltimore, MD 21201 1595, USA
    J Clin Oncol 23:5774-8. 2005
    ..Unfortunately, a plateau in efficacy with currently available agents has been reached. Previous studies of the retinoid, bexarotene, a retinoid X receptor-specific ligand, have indicated that it may improve outcome in advanced NSCLC...
  10. ncbi Lung cancer - Second Annual Winter Conference
    Martin J Edelman
    University of Maryland, Division of Hematology Oncology, Greenebaum Cancer Center, Baltimore, 21201, USA
    IDrugs 8:366-9. 2005
  11. ncbi Evidence-based approaches to overcoming barriers to clinical trial accrual
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Cancer J 10:288-9. 2004
  12. ncbi Novel cytotoxic agents for non-small cell lung cancer
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Thorac Oncol 1:752-5. 2006
    ..It has also demonstrated some single-agent cytotoxic activity...
  13. ncbi Geographic variation in the second-line treatment of non-small cell lung cancer
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21136, USA
    Semin Oncol 33:S39-44. 2006
    ..These geographic and ethnic differences in toxicity and efficacy will need to be considered in the design and comparison of future clinical trials...
  14. ncbi Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors
    Martin J Edelman
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, USA
    Clin Cancer Res 13:2667-74. 2007
    ..Carboplatin was escalated from an area under the curve (AUC) of 3 to an AUC of 5. UCN-01 was escalated from 50 to 90 mg/m(2)...
  15. doi Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer
    Martin J Edelman
    Division of Medical Oncology, University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Ann Thorac Surg 86:903-10. 2008
    ..This study was designed to determine the ability to intensify our prior approach utilizing hyperfractionated radiation and more aggressive consolidative chemotherapy...
  16. doi Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer
    Martin J Edelman
    University of Maryland, Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Clin Lung Cancer 10:S30-4. 2009
    ..New antimicrotubulin agents, including the epothilones, colchicine-binding antivascular agents, and vinca alkaloids, are also discussed...
  17. doi Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, 22 S Greene Street, Baltimore, MD 21201, United States of America
    Lung Cancer 68:84-8. 2010
    ....
  18. doi Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201 1595, USA
    J Thorac Oncol 4:1550-4. 2009
    ..1 MeV beta radiotherapy. To evaluate the safety of this approach, a phase I dose-escalation study of Re-188 P2045 in SSTR-positive lung cancer was performed...
  19. doi Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201 1595, USA
    J Thorac Oncol 5:110-6. 2010
    ..Because the potential benefits of systemic therapy in patients with BM are uncertain, we analyzed data from a recent phase III study...
  20. doi Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Thorac Oncol 6:786-9. 2011
    ..MGd selectively targets tumor cells, disrupting energy metabolism and repair mechanisms, rendering cells more prone to apoptosis. Preclinical studies with MGd and pemetrexed show significant tumor growth delay in lung cancer cell lines...
  21. doi Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    J Thorac Oncol 6:1902-6. 2011
    ....
  22. ncbi Treatment options for brain metastases in patients with non-small-cell lung cancer
    Sadaf Taimur
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Curr Oncol Rep 5:342-6. 2003
    ..The treatment timing of chemotherapy and radiotherapy should be individualized...
  23. ncbi Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug
    Martin J Edelman
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 S Greene Street, Baltimore, MD 21201, USA
    Cancer Chemother Pharmacol 51:439-44. 2003
    ..Given in vitro data that differentiating activity requires continuous butyrate exposure, the short t1/2 of the drug and a desire to mimic the effects of an intravenous infusion, we evaluated a three times daily schedule...
  24. ncbi Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection
    Martin J Edelman
    Division of Hematology and Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Curr Treat Options Oncol 3:67-73. 2002
    ..New methods of surveillance, postoperative risk stratification, and emerging therapies may alter these recommendations for postoperative surveillance of patients with early stage NSCLC in the future...
  25. ncbi Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel
    M J Edelman
    Cancer Center, University of California Davis, Davis, California, USA
    Cancer 92:146-52. 2001
    ....
  26. ncbi Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines
    M J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore 21201 1595, USA
    Cancer Chemother Pharmacol 48:141-4. 2001
    ..To evaluate in vitro interactions of carboplatin, gemcitabine and paclitaxel in molecularly defined non-small-cell lung cancer lines...
  27. doi Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Division of Hematology Oncology 111H, 22 South Greene Street, Baltimore, MD 21201 1595, USA
    J Clin Oncol 26:848-55. 2008
    ....
  28. ncbi Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Lung Cancer 38:S37-43. 2002
    ..Trials are under way or planned for the addition of novel agents such as C225, UCN-01, PKC-alpha antisense, bexarotene, COX-2 inhibitors and other agents...
  29. ncbi Neoadjuvant chemotherapy in early-stage non-small cell lung cancer
    M J Edelman
    University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, USA
    Expert Rev Anticancer Ther 1:229-35. 2001
    ..Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments...
  30. ncbi The management of the patient undergoing combined modality therapy for locally advanced non-small cell lung cancer
    Martin J Edelman
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Curr Treat Options Oncol 4:45-53. 2003
    ..Therefore, mediastinal sampling must be repeated after chemoradiotherapy and before surgery...
  31. ncbi Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 10:5022-6. 2004
    ....
  32. ncbi New approaches to treatment of metastatic bladder cancer
    M J Edelman
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201 1595, USA
    Curr Oncol Rep 2:379-85. 2000
    ..Recently, a number of new chemotherapeutic agents have become available. This report summarizes the current experience with these agents and combinations...
  33. ncbi Promising new agents in the treatment of non-small cell lung cancer
    M J Edelman
    Division of Hematology and Oncology, University of California, Davis, USA
    Cancer Chemother Pharmacol 37:385-93. 1996
    ..The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed...
  34. ncbi Optimal duration of chemotherapy in advanced non-small cell lung cancer
    Maryam B Lustberg
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Curr Treat Options Oncol 8:38-46. 2007
    ....
  35. ncbi Advanced non-small cell lung cancer
    M J Edelman
    University of Maryland Greenebaum Cancer Center, 22 S. Greene Street, Baltimore, MD 21201-1595, USA
    Curr Treat Options Oncol 2:51-62. 2001
    ..A plethora of new agents targeting angiogenesis, tumor invasiveness, the hypoxic environment of tumors, and the cell cycle are currently in development...
  36. ncbi Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
    P N Lara
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento 95817, USA
    Cancer Chemother Pharmacol 48:22-8. 2001
    ..In view of these findings, we hypothesized that toremifene would reverse platinum resistance and that this interaction would be influenced by tumor estrogen receptor (ER) status...
  37. doi Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer
    Amy J Davidoff
    Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland Baltimore, 220 Arch St, 12th Floor, Room 214, Baltimore, MD 21201, USA
    J Clin Oncol 28:2191-7. 2010
    ..This study extends recent population-based analyses focusing on treatment and survival benefit from use of platinum-doublet therapy, and addressing the role of performance status (PS)...
  38. ncbi Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer
    Martin J Edelman
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201 1595, USA
    Lung Cancer 39:197-9. 2003
    ..Based upon promising Phase 1 data, a multicenter trial was performed to evaluate the drug in previously treated non-small cell lung cancer (NSCLC)...
  39. ncbi Recent developments in the chemotherapy of advanced esophageal cancer
    M J Edelman
    Division of Hematology Oncology, Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, USA
    Chest Surg Clin N Am 10:561-7. 2000
    ..Numerous agents with potential activity in esophageal carcinoma based on their putative mechanisms of action are in development. Only clinical trials can establish the role of these agents in the clinic...
  40. ncbi Phase I study of docetaxel and topotecan in patients with solid tumors
    K H Tkaczuk
    University of Maryland Greenebaum Cancer Center, 22 South Greene St, Baltimore, MD 21201, USA
    Cancer Chemother Pharmacol 46:442-8. 2000
    ....
  41. ncbi New directions in the treatment of non-small cell lung cancer: an overview
    M J Edelman
    University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland 21201 1595, USA
    Oncologist 6:1-3. 2001
    ..Clearly, vinorelbine is an active agent which is well tolerated and suitable for use in the management of NSCLC. It is likely to play a greater role in the future...
  42. doi Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer
    Benjamin B Bridges
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Lung Cancer 61:61-6. 2008
    ..We evaluated the efficacy of sequential, dose attenuated carboplatin/gemcitabine followed by paclitaxel in patients with PS=2,3, HIV infection or after solid organ transplantation...
  43. doi Pemetrexed-induced typhlitis in non-small cell lung cancer
    Marianna Shvartsbeyn
    Department of Internal Medicine, University of Maryland, Baltimore, Maryland, USA
    J Thorac Oncol 3:1188-90. 2008
    ..Nevertheless, it is increasingly recognized as a complication of therapy in solid tumors. We present the first documented case of typhilitis after treatment with pemetrexed and successful therapy with supportive treatment...
  44. doi Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery
    Todd W Flannery
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Int J Radiat Oncol Biol Phys 72:19-23. 2008
    ..To report the outcome of patients with synchronous, solitary brain metastasis from non-small-cell lung cancer (NSCLC) treated with gamma knife stereotactic radiosurgery (GKSRS)...
  45. ncbi Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery
    Ashish B Patel
    Department of Radiation Oncology, University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA
    Int J Radiat Oncol Biol Phys 60:1106-12. 2004
    ..To evaluate possible clinical and dosimetric predictors of acute esophagitis in patients with locally advanced non-small-cell lung carcinoma treated in a prospective Phase I-II trimodality protocol...
  46. ncbi Gemcitabine in combination with new platinum compounds: an update
    D R Gandara
    Division of Hematology/Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
    Oncology (Williston Park) 15:13-7. 2001
    ..Here we review recent studies investigating gemcitabine plus carboplatin and preliminary data regarding combinations of gemcitabine with the new platinum analog oxaliplatin...
  47. ncbi Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy
    Roger Hakimian
    University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
    J Thorac Oncol 2:268-72. 2007
    ..There is a very limited literature regarding the treatment and outcome of patients with both diseases, particularly since the advent of highly active antiretroviral therapy (HAART) for HIV infection...
  48. ncbi Phase I trial of gemcitabine and paclitaxel in advanced solid tumors
    Nelson Lim
    Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis School of Medicine, Sacramento, California, USA
    Cancer Invest 21:7-13. 2003
    ..We therefore conducted a phase I trial of a 21-day schedule of weekly gemcitabine and paclitaxel to determine the tolerability, maximum tolerated dose (MTD), and preliminary estimates of efficacy of this regimen...
  49. ncbi Neoadjuvant chemotherapy and chemoradiotherapy for non-small cell lung cancer: current status and future prospects
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, MD, USA
    Expert Opin Pharmacother 4:843-52. 2003
    ..Current research is focusing on the role of newer drugs including novel antitubulin agents, growth factor receptor antagonists, eicosanoid modulators and various other agents...
  50. doi Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation
    Mark J Krasna
    St Joseph Cancer Institute, Towson, University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland 21204, USA
    Ann Thorac Surg 89:200-6; discussion 206. 2010
    ..We studied the clinical characteristics and outcomes of patients undergoing pneumonectomy after preoperative concurrent chemoradiation for non-small cell lung cancer...
  51. ncbi Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
    Philip C Mack
    Cancer and Molecular Research Laboratory, Division of Hematology Oncology, Department of Internal Medicine, University of California, Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Cancer Chemother Pharmacol 51:337-48. 2003
    ..UCN-01 has additional effects on cell cycling, including induction of an RB-associated G(1) arrest...
  52. ncbi Management of common symptoms of advanced lung cancer
    Michelle Bedor
    University of Maryland Greenebaum Cancer Center, 22 S Greene Street, Baltimore, MD 21201, USA
    Curr Treat Options Oncol 6:61-8. 2005
    ..Understanding of coping strategies may aid the medical provider in assisting the patient during his or her illness...
  53. ncbi The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines
    Elizabeth K Balcer-Kubiczek
    Department of Radiation Oncology, Radiation Oncology Research Laboratory, Universtity of Maryland School of Medicine, 655 W Baltimore Street, BRB 6 009, Baltimore, MD 21201, USA
    Cancer Chemother Pharmacol 59:781-7. 2007
    ....
  54. ncbi Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma
    Primo N Lara
    Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 100:82-8. 2004
    ..However, the toxicities of platinum-based chemotherapy are considerable. Regimens with reduced toxicity that are applicable to a broader group of TCC patients without sacrificing activity therefore are of interest...
  55. ncbi Promoter methylation and response to chemotherapy and radiation in esophageal cancer
    James P Hamilton
    Division of Gastroenterology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Clin Gastroenterol Hepatol 4:701-8. 2006
    ..Accordingly, our aim was to find methylation markers that could be used to predict response to chemoradiation...
  56. pmc The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis
    M J Edelman
    Division of Hematology and Oncology, Veterans Affairs Northern California Health Care System, Martinez 94553, USA
    J Gen Intern Med 12:318-31. 1997
    ..Though data are limited, this more restrictive policy of follow-up testing does not appear to adversely impact patient quality of life and result in dramatic cost of savings to the health care system...
  57. pmc A novel, broad-spectrum anticancer compound containing the imidazo[4,5-e][1,3]diazepine ring system
    Min Xie
    Laboratory for Drug Design and Synthesis, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, Baltimore, Maryland 21250, USA
    Bioorg Med Chem Lett 20:4386-9. 2010
    ..The long alkyl chain attached to the six-position of the heterocyclic ring of 1 appears to be necessary for the observed biological activity...
  58. ncbi Treatment options for brain metastases in patients with non-small cell lung cancer
    Sadaf Taimur
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Curr Treat Options Oncol 4:89-95. 2003
    ..The treatment timing of chemotherapy and radiotherapy should be individualized...
  59. doi Successful treatment of small cell lung cancer during pregnancy
    Paul G Kluetz
    University of Maryland, Department of Internal Medicine, MD 21201, United States
    Lung Cancer 61:129-30. 2008
    ..We report a case of a pregnant female with limited stage small cell lung carcinoma treated at 27 weeks gestation with cisplatin and etoposide and subsequent delivery of a healthy child...
  60. pmc MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells
    Minu K Srivastava
    Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250, USA
    Int J Cancer 127:2612-21. 2010
    ....
  61. ncbi Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Cancer Invest 21:1-6. 2003
    ..Tamoxifen has been reported to enhance the antitumor activity of cisplatin in preclinical models by modulation of protein kinase C signal transduction and apoptosis-related pathways...
  62. ncbi High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival
    King F Kwong
    Division of Thoracic Surgery, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, MD, USA
    J Thorac Cardiovasc Surg 129:1250-7. 2005
    ..We sought to study the clinical characteristics and outcomes of patients treated with a surgery-inclusive multimodality approach for Pancoast tumors...
  63. ncbi Management of paraneoplastic syndromes in lung cancer
    Leno Thomas
    Division of Hematology Oncology, Greenebaum Cancer Center, University of Maryland Medical Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Curr Treat Options Oncol 5:51-62. 2004
    ..Specific recommendations for the management of the most common paraneoplastic syndromes, including cachexia, hypercalcemia, and hyponatremia, are provided...
  64. doi Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias
    Ken Shiozawa
    Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center, and Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Cancer Res 15:1698-707. 2009
    ..In this preclinical study, we evaluated combining cytosine arabinoside [1-beta-D-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias...
  65. doi KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells
    Pornima Phatak
    Department of Pharmacology, Cytogenetics Laboratory, University of Maryland, Baltimore, MD, USA
    Clin Cancer Res 14:4593-602. 2008
    ..In this study, we elucidated the mode of action of KML001 and investigated its effects on telomerase and telomeres...
  66. ncbi Cancer stem cells and individualized therapy
    Saranya Chumsri
    Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Cancer Genomics Proteomics 4:165-74. 2007
    ..Here, we provide a current overview of cancer stem cell biology and highlight possibilities for targeted intervention with existing and novel experimental anticancer agents...
  67. ncbi Bronchogenic carcinoma in solid organ transplant recipients
    Yanis Bellil
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Curr Treat Options Oncol 7:77-81. 2006
    ..Treatment is similar to that of patients who are nontransplanted with similar stage, histology, and performance status...
  68. ncbi West Nile virus presenting as opsoclonus-myoclonus cerebellar ataxia
    Jaswinder S Khosla
    Department of Neurology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Neurology 64:1095. 2005
  69. pmc Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells
    Minu K Srivastava
    Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA
    Cancer Immunol Immunother 57:1493-504. 2008
    ..The absence of invariant chain promotes the presentation of endogenously synthesized tumor antigens, and the activation of MHC II-restricted, tumor-antigen-specific CD4(+) T cells...
  70. ncbi Lung cancer in women: emerging differences in epidemiology, biology, and therapy
    Leno Thomas
    University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
    Chest 128:370-81. 2005
    ..These differences in both biology and outcome will be important considerations in the design of future trials of screening and therapy for lung cancer...
  71. ncbi Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium
    Robert Dreicer
    Department of Hematology Oncology and Urologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer 100:1639-45. 2004
    ..The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) were compared in patients with advanced urothelial carcinoma...
  72. ncbi Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?
    Martin J Edelman
    Expert Rev Anticancer Ther 3:127-9. 2003
  73. ncbi Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer
    Joshua R Sonett
    Division of Cardiothoracic Surgery, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York 10032, USA
    Ann Thorac Surg 78:1200-5; discussion 1206. 2004
    ..Operative results and midterm survival follow-up are presented...
  74. ncbi Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713
    Martin J Edelman
    Southwest Oncology Group S9713, Operations Office, 14980 Omicron Drive, San Antonio, TX 78245 3217, USA
    J Clin Oncol 22:127-32. 2004
    ..S9713 evaluated the substitution of paclitaxel and carboplatin for PE consolidation in LSCLC...
  75. ncbi Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer
    Paul Ritch
    Milwaukee Medical College, Milwaukee, USA
    Lung Cancer 52:173-80. 2006
    ..The addition of aprinocarsen to gemcitabine+carboplatin therapy in patients with NSCLC showed moderate activity. However, this combination resulted in severe thrombocytopenia in the majority of patients...
  76. ncbi Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
    Charles M Rudin
    University of Chicago, Illinois, USA
    J Clin Oncol 22:1110-7. 2004
    ..A dose-finding study was performed evaluating the combination of G3139, carboplatin, and etoposide in patients with previously untreated extensive stage SCLC...
  77. ncbi Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
    Antonius A Miller
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
    J Clin Oncol 25:3055-60. 2007
    ..We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction...
  78. doi Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer
    Frank C Detterbeck
    Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut 06520 8062, USA
    J Thorac Oncol 3:37-45. 2008
    ..Surgical resection alone remains suboptimal for patients with early-stage (I or II) non-small cell lung cancer. Two similar randomized phase II trials were conducted to define an active preoperative regimen in this disease state...
  79. doi Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials
    Primo N Lara
    University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA
    J Clin Oncol 26:463-7. 2008
    ....
  80. ncbi Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study
    Quynh Thu Le
    Department of Radiation Oncology, Stanford University, Stanford, California 94305 5847, USA
    Clin Cancer Res 10:5418-24. 2004
    ..To determine the feasibility and a recommended phase II dose of tirapazamine when combined with chemoradiotherapy in limited-stage small cell lung cancer (LSCLC)...
  81. ncbi Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 6:102-7. 2004
    ..06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC...

Research Grants2

  1. CANCER AND LEUKEMIA GROUP B
    Martin Edelman; Fiscal Year: 2002
    ..The grant will also allow for continuation of meritorious pilot protocols and will allow GCC to monitor and collect data which will produce mutual benefit to the GCC and CALGB. ..
  2. PHASE I TRIALS OF ANTICANCER AGENTS
    Martin Edelman; Fiscal Year: 2002
    ....